Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents

  • Daniela Rivera-Pérez
  • , Constanza Méndez
  • , Benjamín Diethelm-Varela
  • , Felipe Melo-González
  • , Yaneisi Vázquez
  • , Xing Meng
  • , Qianqian Xin
  • , Rodrigo A. Fasce
  • , Jorge Fernández
  • , Judith Mora
  • , Eugenio Ramirez
  • , Mónica L. Acevedo
  • , Fernando Valiente-Echeverría
  • , Ricardo Soto-Rifo
  • , Alba Grifoni
  • , Daniela Weiskopf
  • , Alessandro Sette
  • , Patricio Astudillo
  • , Nicole Le Corre
  • , Katia Abarca
  • Cecilia Perret, Pablo A. González, Jorge A. Soto, Susan M. Bueno, Alexis M. Kalergis

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Vaccine effectiveness against SARS-CoV-2 infection has been somewhat limited due to the widespread dissemination of the Omicron variant, its subvariants, and the immune response dynamics of the naturally infected with the virus. Methods: Twelve subjects between 3-17 years old (yo), vaccinated with two doses of CoronaVac®, were followed and diagnosed as breakthrough cases starting 14 days after receiving the second dose. Total IgGs against different SARS-CoV-2 proteins and the neutralizing capacity of these antibodies after infection were measured in plasma. The activation of CD4+ and CD8+ T cells was evaluated in peripheral blood mononuclear cells stimulated with peptides derived from the proteins from the wild-type (WT) virus and Omicron subvariants by flow cytometry, as well as different cytokines secretion by a Multiplex assay. Results: 2 to 8 weeks post-infection, compared to 4 weeks after 2nd dose of vaccine, there was a 146.5-fold increase in neutralizing antibody titers against Omicron and a 38.7-fold increase against WT SARS-CoV-2. Subjects showed an increase in total IgG levels against the S1, N, M, and NSP8 proteins of the WT virus. Activated CD4+ T cells showed a significant increase in response to the BA.2 subvariant (p<0.001). Finally, the secretion of IL-2 and IFN-γ cytokines showed a discreet decrease trend after infection in some subjects. Conclusion: SARS-CoV-2 infection in the pediatric population vaccinated with an inactivated SARS-CoV-2 vaccine produced an increase in neutralizing antibodies against Omicron and increased specific IgG antibodies for different SARS-CoV-2 proteins. CD4+ T cell activation was also increased, suggesting a conserved cellular response against the Omicron subvariants, whereas Th1-type cytokine secretion tended to decrease. Clinical Trial Registration: clinicaltrials.gov

Original languageEnglish
Article number1372193
JournalFrontiers in Immunology
Volume15
DOIs
Publication statusPublished - 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • breakthrough cases
  • CoronaVac
  • inactivated SARS-CoV-2 vaccine
  • omicron variant
  • pediatric
  • phase 3 clinical trial
  • SARS-CoV-2

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents'. Together they form a unique fingerprint.

Cite this